Cardioprotective effect of liposomal prostaglandin E1 on a porcine model of myocardial infarction reperfusion no-reflow

Abstract

Abstract:Objective: To evaluate whether liposomal prostaglandin E1 (lipo-PGE1) can decrease reperfusion no-reflow in a catheter-based porcine model of acute myocardial infarction (AMI). Methods: Twenty-two male Chinese mini-swines were randomized into three groups: six in a sham-operation group, and eight each in the control and lipo-PGE1 groups. The distal part of the left anterior descending coronary artery (LAD) in the latter two groups was completely occluded for 2 h, and then reperfused for 3 h. Lipo-PGE1 (1 μg/kg) was injected 10 min before LAD occlusion until reperfusion for 1 h in the lipo-PGE1 group. Hemodynamic data and proinflammatory cytokines were examined before AMI, 2 h after occlusion, and 1, 2, and 3 h after reperfusion. Myocardial contrast echocardiography (MCE) and double staining were performed to evaluate the myocardial no-reflow area (NRA). Results: Left ventricular systolic pressure and end-diastolic pressure significantly improved in the lipo-PGE1 group after reperfusion compared with the control group and also 2 h after AMI (P<0.05 for both). MCE and double staining both showed that lipo-PGE1 decreased reperfusion NRA after AMI (P<0.05, P<0.01). Lipo-PGE1 decreased serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) after myocardial infarction reperfusion (P<0.05 for both). Conclusions: Lipo-PGE1 is cardioprotective in our porcine model of myocardial infarction reperfusion no-reflow, decreasing NRA and attenuating the inflammatory response.

Effect of Intravenous Administration of Liposomal Prostaglandin E1 on Microcirculation in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention

“…[ 25 ] Another experimental porcine model, of myocardial infarction reperfusion no-reflow, reported that Lipo-PGE1 is cardioprotective and decreases the no-reflow area while attenuating the inflammatory response. [ 10 ] This, in some ways, may explain the improvement of coronary microcirculation (cTFC and MBG) in our study. During 6-month follow-up, we found that patients receiving intravenous Lipo-PGE1 had less MACE, which was consistent with previously published studies.…”

“…However, experimental and clinical studies have demonstrated that myocardial impairment, known as reperfusion injury, may occur as a result of reperfusion. Recent reports have determined that the reperfusion injury is improved by administration of verapamil,[ 2 ] nicorandil,[ 3 4 5 ] adenosine,[ 6 7 ] nitroprusside,[ 8 ] anisodamine,[ 9 ] or prostaglandin E1 (PGE1)[ 10 11 ]. PGE1 reduces free radical production in stimulated human neutrophils and may attenuate reperfusion injury.…”

Low circulating dihomo-gamma-linolenic acid is associated with diabetic retinopathy: a cross sectional study of KAMOGAWA-DM cohort study

“…PGs2 are generally known as pro-inflammatory metabolites, whereas PGs1 possess anti-inflammatory effects [34]. Prostaglandins E1 (PGE1), which is a type of PGs1, could inhibit the proliferation of vascular smooth muscle cells and the adhesion of vascular cells, and the development of atherosclerosis [35,36]. Furthermore, DGLA is metabolized by the 15lipoxygenase into 15-(S)-hydroxy-8,11,13-eicosatrienoic acid (15-HETrE) [37] , which has been reported to reduce the development of DR because it inhibits the activity of vasoconstrictors and metabolites of AA including thromboxanes (TXs) and leukotrienes (LTs) [38,39].…”

Effects of Liposomal Prostaglandin E1 on Coronary Stenosis and Restenosis after Percutaneous Coronary Intervention: A Prospective Clinical Trial

“…Previous studies showed that lipo-PGE1 can decrease coronary restenosis in a canine thrombolysis model 5 and reduce the incidence of periprocedural myocardial injury both in patients 6 and porcrine. 7 Lipo-PGE1 was also found to be effective for improving microcirculation. 8 The nanoliposome delivery system is also a popular method for targeted drug delivery, 9 and reviews have indicated that targeted nanoparticlemediated delivery of multifunctional drugs could be a promising approach to prevent or treat restenosis.…”